Bioengineered solutions to improve cancer immunotherapies

Ther Deliv. 2021 May;12(5):339-341. doi: 10.4155/tde-2021-0019. Epub 2021 Mar 17.
No abstract available

Keywords: bispecific antibodies; half-life extension; human serum albumin; immunotherapy; oncology; protein engineering; recombinant antibodies.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunotherapy*
  • Neoplasms* / therapy